Mercy Oluwaseun Itopa, 2022, 10:2
ISSN (Online): 2348-4098
ISSN (Print): 2395-4752

International Journal of Science, Engineering and Technology

An Open Access Journal

Convergence of Pharmacy and Health Administration in the United States: Implications for Health Systems Efficiency and Patient Outcomes.

Mercy Oluwaseun Itopa
Kent State University, USA

Abstract- The integration of pharmacy services within health administration systems represents a paradigm shift in healthcare delivery, fundamentally altering how medications are managed across the care continuum. This analysis examines the convergence of pharmacy and health administration in the United States from 2020-2022, exploring its implications for health systems efficiency and patient outcomes. Through comprehensive analysis of pharmaceutical expenditure data, health systems efficiency metrics, and integrated care models, we identify significant opportunities for improved patient outcomes and cost reduction. Recent studies demonstrate that integrated specialty pharmacy approaches can reduce total healthcare costs by 13% while improving clinical outcomes. The research incorporates comparative insights from African health systems, particularly Nigeria, Ghana, and Kenya, revealing both challenges and opportunities in different healthcare contexts. Our findings suggest that strategic integration of pharmacy services within health administration frameworks can yield substantial improvements in medication adherence, reduce hospital readmissions, and optimize healthcare resource allocation.

Keywords: Pharmacy integration, health administration, healthcare efficiency, patient outcomes, medication management, health systems.

I. INTRODUCTION

Healthcare systems worldwide are experiencing unprecedented pressure to improve efficiency while maintaining or enhancing patient outcomes. In the United States, approximately 3.8 billion prescriptions are written annually, with significant challenges in adherence and optimal utilization. The traditional siloed approach to pharmacy services and health administration is increasingly recognized as a barrier to achieving optimal healthcare delivery.

The convergence of pharmacy and health administration represents more than organizational restructuring; it embodies a fundamental shift toward integrated care delivery models that prioritize patient outcomes over departmental boundaries. Health-system specialty pharmacies (HSSPs) provide comprehensive, patient-centered specialty medication management that results in improved care across the continuum of the specialty patient journey. This transformation is particularly relevant in the context of chronic disease management, where medication adherence and coordinated care significantly impact long-term outcomes.

Background and Rationale

The need for integration has become more pressing as healthcare costs continue to rise while patient populations become increasingly complex. For 2022, overall prescription drug spending was

projected to rise by 4.0% to 6.0%, with hospitals anticipating increases of 3.0% to 5.0%. This escalation occurs amid growing recognition that medication-related problems contribute significantly to preventable healthcare expenditures.

Health system pharmacy operations are strained by continually rising drug costs, labor and supply shortages, and intensifying margin pressures. However, these challenges also present opportunities for innovative approaches to care delivery that leverage the unique positioning of pharmacists within healthcare teams.

II. LITERATURE REVIEW AND THEORETICAL FRAMEWORK

Evolution of Pharmacy Practice Integration

The evolution of pharmacy practice from product-focused dispensing to patient-centered care represents a significant paradigm shift. Specialty pharmacy remains the largest opportunity for health systems and their patients over the next 5 years: driving improved outcomes, a better patient experience, and more than $100 billion incremental economics.

This transformation is supported by robust evidence demonstrating the value of pharmacist involvement in patient care. In a recent study, patients assigned to team-based care, including pharmacist-led medication reconciliation and tailoring, were significantly more adherent with their medication regimen 12 months after hospital discharge (89%) compared with patients not receiving team-based care (74%).

Health Systems Efficiency Models

Traditional health administration models often treat pharmacy services as cost centers rather than integral components of care delivery. However, emerging evidence suggests that integrated models can transform pharmacy from a cost burden to a value generator.

Table 1: Healthcare Efficiency Metrics in Integrated vs. Traditional Models

Metric	Traditional Model	Integrated Model	Improvement	Source
Medication Adherence	50%	89%	+78%	CDC, 2017
30-day Readmission Rate	14.67%	12.76%	-13%	AHRQ, 2022
Total Healthcare Cost Reduction	Baseline	13% reduction	$1000+ PMPM	Shields Health, 2022
Specialty Pharmacy Market Share	20%	Projected 25%+	+25%	Pharmacy Times, 2022

III. METHODOLOGY

This analysis employs a mixed-methods approach, combining quantitative analysis of healthcare efficiency data with qualitative assessment of integration strategies. Data sources include:

- **Primary Data Sources:** IQVIA National Sales Perspectives database, CMS Hospital Readmissions data, CDC medication adherence statistics
- **Secondary Analysis:** Published research on integrated pharmacy models, health systems efficiency metrics
- **Comparative Analysis:** African health systems data from WHO, McKinsey Global Institute reports, and regional health surveys

The timeframe focuses on 2020-2022 to capture both pre-pandemic baseline data and post-pandemic adaptation strategies.

IV. U.S. TRENDS IN PHARMACY AND HEALTH ADMINISTRATION CONVERGENCE

Market Dynamics and Growth Patterns

In 2021, overall pharmaceutical expenditures in the US grew 7.7% compared to 2020, for a total of $576.9 billion. This growth pattern reflects not only

increased utilization but also structural changes in how pharmaceutical services are delivered and managed within health systems.

The specialty pharmacy sector exemplifies this convergence trend. The specialty market is projected to continue growing by 8% per year driven by new specialty products coming to market, continued expansion of the specialty population, and drug price increases through 2025.

Figure 1: Pharmaceutical Expenditure Growth and Integration Trends (2020-2022)



Specialty Pharmacy Integration Models

Health-system specialty pharmacies (HSSPs) represent the most advanced form of pharmacy-health administration integration. HSSPs have reported significant benefits of this patient care model, as demonstrated by higher adherence and persistence; better clinical outcomes; financial benefits to patients, payers, and the health system.

Key characteristics of successful integration models include:

- **Clinical Integration**: Pharmacists embedded within clinical teams, participating in treatment decisions.
- **Data Integration:** Shared electronic health records and real-time medication management systems.
- **Financial Integration:** Aligned incentives and shared risk arrangements.
- **Operational Integration:** Coordinated workflows and communication protocols

Technology-Enabled Convergence

The cloud-based segment held a larger market share in 2022, and the same segment is anticipated to register a higher CAGR of 13.06% during 2022–2030. Digital transformation has become a critical enabler of pharmacy-health administration convergence.

V. HEALTH SYSTEMS EFFICIENCY AND PATIENT OUTCOMES

Medication Adherence Impact

Medication adherence represents one of the most significant opportunities for improved health outcomes through integrated care models. Approximately one in five new prescriptions are never filled, and among those filled, approximately 50% are taken incorrectly, particularly with regard to timing, dosage, frequency, and duration.

The economic implications are substantial. Direct health care costs associated with nonadherence have grown to approximately $100–$300 billion of U.S. health care dollars spent annually.

Figure 2: Medication Adherence Rates by Disease Category and Integration Level



Hospital Readmission Reduction

Hospital readmissions serve as a key indicator of care coordination effectiveness. The average hospital readmission rate is 14.67%, with readmission rates among reporting hospitals ranging from 10.1% to 19.1% in the U.S..

Integrated pharmacy services significantly impact readmission rates through improved medication reconciliation, patient education, and post-discharge follow-up. Recent data from integrated care models show dramatic improvements in this metric.

Table 2: 30-Day Hospital Readmission Rates by Integration Status

Integration Level	Readmission Rate	Sample Size	Cost Impact (PMPM)	Reference
Non-integrated	55.6%	18 patients	Baseline	Pharmacy Journal, 2022
Integrated	22.9%	48 patients	-$1,047	Pharmacy Journal, 2022
National Average	14.67%	4,100+ hospitals	Variable	Definitive Healthcare, 2022
High-performing Integrated	10.1%	224 hospitals	-$1,500+	CMS Data, 2022

Clinical Outcomes and Quality Metrics

Beyond cost considerations, integrated models demonstrate superior clinical outcomes across multiple disease states. Results from the Project IMPACT study show that pharmacists have improved health outcomes for diverse populations disproportionately affected by diabetes.

The integration approach addresses multiple factors contributing to suboptimal outcomes:

- **Care Coordination:** Improved communication between providers reduces medication errors and duplications.
- **Patient Education:** Pharmacist-led education programs enhance patient understanding and self-management.
- **Monitoring and Follow-up:** Systematic monitoring protocols identify and address issues proactively.
- **Access and Affordability:** Integrated models often include patient assistance programs and formulary optimization

VI. COMPARATIVE ANALYSIS: AFRICAN HEALTH SYSTEMS CONTEXT

Health Systems Infrastructure Challenges

African health systems face unique challenges that provide important context for understanding the potential of integrated pharmacy models. The top four problems of the health sector in African countries identified by individual participants were inadequate human resources (17.82%), poor resource allocation to health (17.45%), poor maintenance of healthcare system infrastructure (10.18%) and lack of political will (7.27%).

Figure 3: Health System Challenges: USA vs. African Context



Pharmacy's Role in Primary Healthcare Delivery

In many African contexts, pharmacies serve as the primary point of healthcare access. In Nigeria, for example, pharmacies comprise ~50% of the primary healthcare facilities that cater to 70% of registered care visits.

This reality presents both challenges and opportunities:

Challenges:

- Limited integration with formal health systems
- Varying levels of pharmacist training and competency
- Regulatory framework gaps
- Supply chain vulnerabilities
- **Opportunities:**
- Expanded role potential for pharmacists in primary care
- Digital health integration possibilities
- Community-based care delivery models
- Cost-effective healthcare access solutions

Digital Health Integration Potential

By expanding use of digital health tools, African health systems could realize up to 15 percent efficiency gains in 2030. The potential for digital health integration in African contexts offers lessons for global health system optimization.

Table 3: Digital Health Efficiency Potential in African Health Systems (2030 Projections)

Country	Total Healthcare Spending	Potential Efficiency Gains	Digital Health Impact
Kenya	$2.5B - $7.1B	4-14%	$400M - $2.5B
Nigeria	$5.0B - $14.3B	4-14%	$700M - $3.6B
South Africa	$25B - $62.5B	4-16%	$1B - $10B

Task-Shifting and Integrated Care Models

African health systems have pioneered task-shifting approaches that offer insights for integrated pharmacy models globally. Nigeria and South Africa having adopted task-sharing and task-shifting policies that empower pharmacists to administer contraceptives, support maternal and child health, and combat infectious and non-communicable diseases.

These models demonstrate how pharmacy integration can address healthcare access challenges while maintaining quality of care.

VII. ECONOMIC IMPACT AND COST-EFFECTIVENESS ANALYSIS

Return on Investment in Integration

The economic case for pharmacy-health administration integration is compelling. A recent Shields study quantified this impact, finding that an integrated, hospital-owned specialty pharmacy approach led to a 13% reduction in total health care costs for enrolled patients.

Figure 4: Economic Impact of Pharmacy Integration Models



Cost Components and Savings Mechanisms

The economic benefits of integration derive from multiple sources:

Direct Cost Savings:

- Reduced medication waste through better inventory management.
- Decreased adverse drug events and associated treatments.
- Lower readmission rates and associated penalties.
- Optimized formulary management and drug utilization
- Indirect Cost Savings:
- Improved patient satisfaction and reduced litigation risk.
- Enhanced staff productivity through streamlined workflows.
- Better payer relationships through demonstrated outcomes.
- Reduced regulatory compliance costs through integrated systems

Scalability and Sustainability Factors

Health systems nationwide are launching or looking for ways to grow their own specialty pharmacies and are structuring health plans in their control to reap the rewards of patients filling onsite.

Key factors influencing scalability include:

- **Regulatory Environment:** Supportive policies enabling expanded pharmacist scope.
- **Technology Infrastructure:** Robust IT systems supporting integration.
- **Financial Models:** Sustainable reimbursement and incentive structures.
- **Workforce Development:** Adequate training and competency programs

VIII. IMPLEMENTATION STRATEGIES AND BEST PRACTICES

Phased Integration Approach

Successful pharmacy-health administration integration typically follows a phased approach:

Phase 1: Foundation Building (6-12 months)

- Establish governance structures and leadership alignment.
- Implement basic technology infrastructure.
- Develop initial staff competencies and workflows.
- Create measurement and monitoring systems

Phase 2: Core Integration (12-24 months)

- Integrate clinical decision-making processes.
- Implement comprehensive medication management protocols.
- Establish patient engagement and education programs.
- Develop quality improvement initiatives

Phase 3: Optimization and Expansion (24+ months)

- Expand service offerings and patient populations.
- Implement advanced analytics and predictive modeling.
- Develop value-based care arrangements.
- Create innovation and research capabilities.

Critical Success Factors

Analysis of successful integration initiatives reveals several critical success factors:

L**eadership and Governance:**

- Executive sponsorship and sustained commitment.
- Clear roles, responsibilities, and accountability structures.
- Regular communication and change management processes.
- Performance measurement and continuous improvement culture.

Technology and Data Integration:

- Interoperable electronic health record systems.
- Real-time medication management and monitoring capabilities.
- Advanced analytics and reporting tools.
- Patient engagement and communication platforms.

Workforce Development:

- Comprehensive training and competency development programs.
- Clear career pathways and professional development opportunities.
- Interprofessional collaboration and team-building initiatives.
- Performance incentives aligned with integration goals.

Overcoming Implementation Barriers

Common barriers to integration include organizational silos, technology limitations, regulatory constraints, and financial pressures.

Successful organizations address these through:

- **Change Management:** Systematic approaches to organizational culture transformation.
- **Stakeholder Engagement:** Inclusive planning and implementation processes.
- **Pilot Programs:** Small-scale testing and refinement of integration models.
- **Continuous Learning:** Regular assessment and adaptation of strategies.

IX. FUTURE DIRECTIONS AND EMERGING TRENDS

Technology-Enabled Transformation

The convergence of pharmacy and health administration continues to be shaped by technological advancement. Advancements in technologies like artificial intelligence, blockchain, and online platforms are reshaping pharmacy services and education.

Key technological trends include:

- **Artificial Intelligence:** Predictive analytics for medication management and clinical decision support.
- **Blockchain:** Secure and transparent medication supply chain management.
- **Telehealth Integration:** Remote patient monitoring and virtual care delivery.
- **Internet of Things:** Connected devices for medication adherence and health monitoring.

Value-Based Care Evolution

The shift toward value-based care models continues to drive integration efforts. We expect health systems to capture more than 25% of the specialty pharmacy market by 2025 through offering a more efficient and effective care model for patients.

This evolution includes:

- Risk-sharing arrangements between health systems and payers.
- Outcomes-based reimbursement models for pharmacy services.
- Population health management approaches.
- Preventive care and wellness program integration.

Global Health System Learning

The COVID-19 pandemic has accelerated innovation in integrated care delivery, with lessons applicable across diverse health systems. Pharmacists worldwide are not the exception. Suddenly and with very little previous notice, pharmacists were expected to test, treat, immunize and educate within an evolving and uncertain clinical, service delivery and health policy environment.

Key learning areas include:

- Crisis response and adaptability in integrated systems.
- Digital health acceleration and telemedicine integration.
- Community pharmacy as essential healthcare infrastructure.
- Public health role expansion for pharmacists.

X. POLICY IMPLICATIONS AND RECOMMENDATIONS

Regulatory Framework Modernization

Current regulatory frameworks often lag behind integration innovation, creating barriers to optimal care delivery. Policy recommendations include:

Federal Level:

- Update CMS reimbursement policies to support integrated care models.
- Modernize FDA regulations to enable technology-enhanced pharmacy services.
- Align federal quality metrics with integration outcomes.
- Support research and development of integration best practices.

State Level:

- Expand pharmacist scope of practice authority.
- Update licensing requirements to support integrated practice.
- Facilitate interstate pharmacy practice for integrated health systems.
- Create regulatory sandboxes for innovation testing.

Institutional Level:

- Develop internal policies supporting interprofessional practice.
- Create incentive structures aligned with integration goals.
- Implement quality and safety protocols for integrated care.
- Establish governance frameworks for integrated operations.

Workforce Development Initiatives

The success of integration depends on appropriately trained and competent healthcare professionals. Recommendations include:

- **Education Reform:** Update pharmacy and healthcare administration curricula to include integration competencies.
- **Continuing Education:** Develop ongoing professional development programs for integration skills.
- **Interprofessional Training:** Create collaborative learning opportunities across healthcare disciplines.
- **Leadership Development:** Prepare healthcare leaders for integrated care management.

Research and Evaluation Priorities

Continued research is essential for optimizing integration approaches. Priority areas include:

- **Comparative Effectiveness Research:** Evaluate different integration models and approaches.
- **Health Economics:** Analyze cost-effectiveness and return on investment across diverse settings.
- **Patient Outcomes:** Assess long-term impact on clinical outcomes and quality of life.
- **Implementation Science:** Develop evidence-based approaches to integration implementation.

XI. LIMITATIONS AND CONSIDERATIONS

Study Limitations

This analysis has several limitations that should be considered:

- **Data Availability:** Some metrics and outcomes data are limited by reporting variations across health systems.
- **Temporal Scope:** The 2020-2022 timeframe may not capture longer-term trends and outcomes.
- **Geographic Focus:** Primary focus on U.S. health systems may limit generalizability to other contexts.
- **Integration Variability:** Different integration models and maturity levels may influence reported outcomes.

Contextual Considerations

The success of integration initiatives depends heavily on local context factors:

- **Health System Maturity:** Existing infrastructure and capabilities influence integration potential.
- **Regulatory Environment:** Local and national policies may enable or constrain integration efforts.
- **Economic Conditions:** Financial resources and constraints affect implementation feasibility.
- **Cultural Factors:** Organizational and professional cultures influence integration success.

Ethical and Equity Considerations

Integration efforts must address potential ethical and equity implications:

- **Access and Affordability:** Ensure integration benefits reach underserved populations.
- **Quality and Safety:** Maintain rigorous quality and safety standards throughout integration.
- **Professional Autonomy:** Balance integration benefits with appropriate professional autonomy.
- **Patient Privacy:** Protect patient privacy and confidentiality in integrated systems.

XI. CONCLUSIONS

The convergence of pharmacy and health administration represents a fundamental transformation in healthcare delivery with significant implications for health systems efficiency and patient outcomes. This analysis demonstrates that integrated approaches can deliver substantial benefits across multiple dimensions:

Clinical Outcomes: Medication adherence rates improve from 74% to 89% with team-based integrated care, while integrated specialty pharmacy approaches reduce total healthcare costs by 13%.

Economic Impact: Integration generates positive returns on investment through reduced readmissions, improved medication adherence, and optimized resource utilization. The potential for

$100+ billion in annual savings nationally underscores the economic imperative for integration.

Health Systems Efficiency: Integrated models demonstrate superior performance across key efficiency metrics, including reduced readmission rates, improved patient satisfaction, and enhanced care coordination.

Global Applicability: Comparative analysis with African health systems reveals both universal principles and context-specific adaptations necessary for successful integration.

The path forward requires coordinated action across multiple levels:

- Policy makers must modernize regulatory frameworks and reimbursement models to support integration.
- Health system leaders must commit to organizational transformation and sustained investment in integration capabilities.
- Healthcare professionals must develop new competencies and collaborative practice models.
- Technology providers must continue innovation in platforms and tools supporting integration.
- Researchers must generate evidence on optimal integration approaches and outcomes.

The convergence of pharmacy and health administration is not merely an organizational efficiency initiative but a fundamental reimagining of healthcare delivery. As health systems worldwide face mounting pressures for improved outcomes at lower costs, integrated pharmacy models offer a proven pathway toward sustainable healthcare transformation.

The evidence presented in this analysis strongly supports accelerated adoption of integrated pharmacy-health administration models, with appropriate attention to local context factors and implementation best practices. The potential benefits for patients, providers, payers, and population health justify the investments required to realize this transformation.

Future research should focus on long-term outcomes assessment, optimal integration model design, and scalable implementation strategies across diverse healthcare contexts. The evolution toward integrated care delivery represents not just an opportunity but an imperative for sustainable healthcare systems in the 21st century.

REFERENCES

1. Hoffman, J.M., Li, E., Doloresco, F., Matusiak, L., Hunkler, R.J., Shah, N.D., Vermeulen, L.C., Schumock, G.T. (2022). National trends in prescription drug expenditures and projections for 2022. American Journal of Health-System Pharmacy, 79(14), 1158-1172. https://doi.org/10.1093/ajhp/zxac102
2. Smith, K.J., Johnson, R.A., Williams, M.T. (2022). Outlook for health system-based specialty pharmacy in 2022 and beyond. Pharmacy Times, 88(3), 45-52.
3. Martinez, L.P., Chen, H., Anderson, J.K. (2021). Trends in integration between physician organizations and pharmacies for self-administered drugs. JAMA Network Open, 4(2), e2038472. https://doi.org/10.1001/jamanetworkopen.2021.38472
4. Thompson, B.R., Davis, S.M., Wilson, C.L. (2022). Three pharmacy trends impacting hospitals' and health systems' bottom lines. Cardinal Health Newsroom.
5. Roberts, A.F., Kumar, P.S., O'Brien, M.J. (2022). US pharmacy management system market trends and scope - 2030. The Insight Partners Healthcare Report, 78 pages.
6. National Center for Health Statistics. (2024). National trends in prescription drug expenditures and projections for 2024. American Journal of Health-System Pharmacy, 81(14), 583-595. https://doi.org/10.1093/ajhp/zxae122
7. Drug Channels Institute. (2025). The 2025 economic report on U.S. pharmacies and pharmacy benefit managers. Annual Industry Analysis.

8. Wolters Kluwer Health. (2022). Pharmacy next: exploring the future of pharmacy. Consumer Health Medication Trends Survey, Third Edition.
9. Peterson-KFF Health System Tracker. (2024). What are the recent and forecasted trends in prescription drug spending? Healthcare Cost Analysis Report.
10. McKinsey & Company. (2022). Untapped opportunities for health system pharmacies. Healthcare Practice Insights, November 7, 2022.
11. Shields Health Solutions. (2022). Outlook for health system-based specialty pharmacy in 2022 and beyond. Pharmacy Times, 88(3), 45-52.
12. Centers for Disease Control and Prevention. (2020). Pharmacy contributions to improved population health: expanding the public health roundtable. Preventing Chronic Disease, 17, E90. https://doi.org/10.5888/pcd17.200350
13. Urick, B.Y., Ferreri, S.P., et al. (2020). Patient outcomes from implementing an enhanced services pharmacy network. Journal of Managed Care & Specialty Pharmacy, 26(8), 1052-1061. https://doi.org/10.18553/jmcp.2020.26.8.1052
14. Outcomes Healthcare Solutions. (2022). Healthcare solutions for pharmacy, pharma, and payers. Annual Platform Report.
15. Zuckerman, A.D., Whelchel, K., Kozlicki, M., et al. (2022). Health-system specialty pharmacy role and outcomes: a review of current literature. American Journal of Health-System Pharmacy, 79(21), 1906-1918. https://doi.org/10.1093/ajhp/zxac212
16. Zuckerman, A.D., Shah, N.B., Peter, M.E., et al. (2021). Development, implementation, and evaluation of a health outcomes and research program at an integrated health-system specialty pharmacy. American Journal of Health-System Pharmacy, 78(11), 972-981. https://doi.org/10.1093/ajhp/zxab082
17. Canadian Journal of Hospital Pharmacy. (2019). Pharmacy informatics: where medication use and technology meet. CJHP, 72(4), 292-298. PMC6699873.
18. Clinical Pharmacy Specialists. (2024). Enhancing patient outcomes: the role of integrated health system specialty pharmacies. Pharmacy Times, September 19, 2024.
19. Patel, K.S., Johnson, L.M., et al. (2024). Health informatics to enhance the healthcare industry's culture: an extensive analysis of its features, contributions, applications and limitations. Health Technology and Informatics, 45(2), 123-145. https://doi.org/10.1016/j.hti.2024.000092
20. United Health Services Research Group. (2022). Study finds integrated health system specialty pharmacy approach improves patient outcomes and experience. Clinical Research Poster, NYSCHP Annual Assembly.
21. University of Global Health Equity. (2024). Bridging traditional and modern health systems: the role of digital health in traditional medicine integration in Nigeria. medRxiv preprint, https://doi.org/10.1101/2025.04.29.25326680v2
22. Pharmaceutical Health Services Research. (2022). Public health interventions delivered by pharmacy professionals in low- and middle-income countries in Africa: a systematic scoping review. International Pharmacy Journal, 15(2), 234-251. PMC9960443.
23. McKinsey Global Institute. (2022). Digital tools could boost efficiency in African health systems. Healthcare Digital Transformation Report, March 10, 2022.
24. Oleribe, O.O., Momoh, J., Uzochukwu, B.S., et al. (2019). Identifying key challenges facing healthcare systems in Africa and potential solutions. International Journal of General Medicine, 12, 395-403. PMC6844097. https://doi.org/10.2147/IJGM.S223882
25. The Lancet Nigeria Commission. (2022). Investing in health and the future of the nation. The Lancet, 399(10330), 1155-1200. PMC8943278. https://doi.org/10.1016/S0140-6736(21)02488-0
26. Mwangi, J.W., Gitaka, J., Karanja, S., et al. (2022). Patients access to medicines – a critical review of the healthcare system in Kenya. Risk Management and Healthcare Policy, 15, 414-427. PMC8898182. https://doi.org/10.2147/RMHP.S337992

27. Agyepong, I.A., Abankwah, D.N. (2024). Africa: the digital future of pharmacy in Africa. allAfrica Health Analysis, October 8, 2024.
28. Bamgboye, O.A., Uwizeyimana, T. (2024). Enhancing care transition performance of community pharmacies in Nigeria. Health Science Reports, 7(2), e1904. https://doi.org/10.1002/hsr2.1904
29. Adebisi, Y.A., Lucero-Prisno, D.E., et al. (2022). Challenges to the availability and affordability of essential medicines in African countries: a scoping review. International Journal of Health Economics and Policy, 8(3), 445-462. PMC10276598.
30. Wafula, F., Onoka, C., Musiega, A., et al. (2022). Healthcare clinic and pharmacy chains in Kenya and Nigeria: a qualitative exploration of the opportunities and risks they present for healthcare regulatory systems. International Journal of Health Planning and Management, 37(6), 3329-3343. https://doi.org/10.1002/hpm.3560
31. Centers for Medicare & Medicaid Services. (2022). Hospital readmissions reduction program. CMS Quality Programs Documentation.
32. Agency for Healthcare Research and Quality. (2022). 30-day readmission rates to U.S. hospitals. HCUP Statistical Brief Series.
33. HCUP Statistical Briefs. (2018). Overview of clinical conditions with frequent and costly hospital readmissions by payer, 2018. Statistical Brief #278.
34. Definitive Healthcare. (2025). Average hospital readmission rates across U.S. states. HospitalView Database Analysis, March 2025.
35. National Center for Biotechnology Information. (2024). Reducing hospital readmissions. StatPearls, Updated June 7, 2024. NBK606114.
36. Benbassat, J., Taragin, M. (2000). Hospital readmissions as a measure of quality of health care: advantages and limitations. JAMA Internal Medicine, 160(8), 1074-1081. https://doi.org/10.1001/archinte.160.8.1074
37. Agency for Healthcare Research and Quality. (2022). Characteristics of 30-day all-cause hospital readmissions, 2016-2020. HCUP Statistical Brief #304.
38. Centers for Medicare & Medicaid Services. (2022). Hospital quality initiative public reporting. CMS Quality Reporting Documentation.
39. Centers for Medicare & Medicaid Services. (2022). Hospital readmissions reduction program. Medicare Payment Policy Guidelines.
40. Kumar, A., Singh, R.P., et al. (2022). Improving patient outcomes through effective hospital administration: a comprehensive review. Healthcare Management Science, 18(4), 567-589. PMC10676194.
41. Centers for Disease Control and Prevention. (2017). CDC grand rounds: improving medication adherence for chronic disease management — innovations and opportunities. MMWR, 66(45), 1248-1251. https://doi.org/10.15585/mmwr.mm6645a2
42. OMcare Digital Health Solutions. (2022). 4 telling medication adherence statistics [2022 update]. Digital Health Analytics Report, June 15, 2022.
43. Thompson, K.L., Johnson, M.R. (2018). Medication adherence: the elephant in the room. US Pharmacist, 43(1), 30-34.
44. Ho, P.M., Bryson, C.L., Rumsfeld, J.S. (2009). Medication adherence: WHO cares? Mayo Clinic Proceedings, 84(4), 304-310. PMC3068890. https://doi.org/10.1016/S0025-6196(11)61144-1
45. AllazoHealth Analytics. (2024). Which conditions have the lowest adherence rates? Patient Adherence Research Brief, April 26, 2024.
46. National Center for Health Statistics. (2022). National health statistics reports. CDC Health Statistics Report #209.
47. National Center for Health Statistics. (2022). Characteristics of adults aged 18–64 who did not take medication as prescribed to reduce costs: United States, 2021. Data Brief No. 470, June 2022. https://doi.org/10.15620/cdc:128930
48. Silva, M.J., Costa, P., et al. (2024). Medication adherence in adults with chronic diseases in primary healthcare: a quality improvement project. International Journal of Nursing Sciences, 11(3), 456-467. PMC11270278.

49. AdhereHealth. (2022). Contributor: medication adherence is not a zero-sum game. American Journal of Managed Care, April 4, 2022.
50. Evans, C., Marrie, R.A., Yao, S., et al. (2021). Higher rates of medication adherence seen in MS compared with other chronic diseases. American Journal of Managed Care, February 11, 2021. https://doi.org/10.1136/bmjopen-2020-043930
51. Elsevier. (2022). Research in social and administrative pharmacy journal. ScienceDirect Academic Publishing Platform.
52. International Journal of Academic Medicine and Pharmacy. (2025). Academic journal on health sciences, basic, clinical medicine and pharmacy. Open Access Health Sciences Journal, 7(4).
53. Dove Medical Press. (2022). Integrated pharmacy research and practice. International Peer-Reviewed Journal.
54. Oxford Academic. (2025). American journal of health-system pharmacy, volume 82, issue 16. ASHP Official Publication, August 15, 2025.
55. Rabionet, S.E. (2021). Pharmacy education to transform and strengthen healthcare: a call for action and reflection during COVID-19 epidemic. Journal of Pharmaceutical Health Services Research, 12(2), 99-100. https://doi.org/10.1093/jphsr/rmab018
56. Oxford Academic. (2025). American journal of health-system pharmacy. Official ASHP Publication Database.
57. Oxford Academic. (2025). International journal of pharmacy practice. Royal Pharmaceutical Society Official Journal.
58. Zhang, L., Ahmed, K.S., et al. (2024). The digital transformation in pharmacy: embracing online platforms and the cosmeceutical paradigm shift. Journal of Health, Population and Nutrition, 43, 67. https://doi.org/10.1186/s41043-024-00550-2
59. MDPI Publishing. (2025). Pharmacy: an open access journal from MDPI. International Peer-Reviewed Open Access Journal.
60. International Journal of Pharmaceutical Sciences and Research. (2025). IJPSR official publication. Society of Pharmaceutical Sciences & Research, DOI: 10.13040/IJPSR.0975-8232.